Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Smolen

Showing results (71-80 of 863) with videos related to

Pageof 87
Sort By:
Acta Medica Austriaca|March 20, 2002
Advances in anti-inflammatory therapyD Aletaha, J S Smolen
Acta Medica Austriaca|January 1, 1988
[The pathogenesis of systemic lupus erythematosus--data and considerations]W Graninger, J S Smolen
Expert Opinion on Drug Safety|July 11, 2008
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Current Pharmaceutical Design|September 24, 2005
New insights in the mechanism of bone loss in arthritisGeorg Schett, Josef S Smolen
Clinical and Experimental Rheumatology|October 17, 2013
The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trialsArthur Kavanaugh, Josef S Smolen
Clinical and Experimental Rheumatology|November 4, 2014
Scores for all seasons: SDAI and CDAIJ S Smolen, D Aletaha
Nature Clinical Practice. Rheumatology|May 8, 2008
Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritisJosef S Smolen, Daniel Aletaha
Arthritis and Rheumatism|May 20, 1998
Mixed connective tissue disease: to be or not to be?J S Smolen, G Steiner
JAMA|October 5, 2018
Diagnosis and Management of Rheumatoid Arthritis: A ReviewDaniel Aletaha, Josef S Smolen
Nature Reviews. Rheumatology|February 4, 2011
Rheumatoid arthritis in 2010: from the gut to the jointClemens Scheinecker, Josef S Smolen
Pageof 87

Showing results (71-80 of 863) with videos related to

Sort By:
Pageof 87
Acta Medica Austriaca|March 20, 2002
Advances in anti-inflammatory therapyD Aletaha, J S Smolen
Acta Medica Austriaca|January 1, 1988
[The pathogenesis of systemic lupus erythematosus--data and considerations]W Graninger, J S Smolen
Expert Opinion on Drug Safety|July 11, 2008
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosusMartin Aringer, Josef S Smolen
Current Pharmaceutical Design|September 24, 2005
New insights in the mechanism of bone loss in arthritisGeorg Schett, Josef S Smolen
Clinical and Experimental Rheumatology|October 17, 2013
The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trialsArthur Kavanaugh, Josef S Smolen
Clinical and Experimental Rheumatology|November 4, 2014
Scores for all seasons: SDAI and CDAIJ S Smolen, D Aletaha
Nature Clinical Practice. Rheumatology|May 8, 2008
Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritisJosef S Smolen, Daniel Aletaha
Arthritis and Rheumatism|May 20, 1998
Mixed connective tissue disease: to be or not to be?J S Smolen, G Steiner
JAMA|October 5, 2018
Diagnosis and Management of Rheumatoid Arthritis: A ReviewDaniel Aletaha, Josef S Smolen
Nature Reviews. Rheumatology|February 4, 2011
Rheumatoid arthritis in 2010: from the gut to the jointClemens Scheinecker, Josef S Smolen
Pageof 87